Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dabrafenib with or without trametinib in BRAF V600E-mutant metastatic non-small cell lung cancer
NL-OMON47910Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Novartis. Primary endpoint: Overall response rate. Started May 2013; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON47910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47910.